Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) Director Muneer A. Satter bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 30th. The stock was bought at an average price of $1.98 per share, with a total value of $118,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

OTCMKTS ARPO opened at $2.10 on Thursday. Aerpio Pharmaceuticals Inc has a 12-month low of $1.75 and a 12-month high of $5.50.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last posted its quarterly earnings results on Wednesday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.34 by ($0.06). The business had revenue of $18.82 million for the quarter, compared to analyst estimates of $18.67 million.

Large investors have recently modified their holdings of the company. Millennium Management LLC bought a new position in Aerpio Pharmaceuticals in the second quarter worth about $934,000. Nexthera Capital LP bought a new position in Aerpio Pharmaceuticals in the second quarter worth about $1,240,000. FMR LLC bought a new position in Aerpio Pharmaceuticals in the second quarter worth about $3,648,000. Vanguard Group Inc. bought a new position in Aerpio Pharmaceuticals in the third quarter worth about $3,331,000. Finally, Sphera Funds Management LTD. raised its stake in Aerpio Pharmaceuticals by 2.6% in the third quarter. Sphera Funds Management LTD. now owns 1,131,819 shares of the company’s stock worth $3,497,000 after buying an additional 28,265 shares in the last quarter. 0.37% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on the stock. HC Wainwright set a $9.00 target price on shares of Aerpio Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 8th. Zacks Investment Research lowered shares of Aerpio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Finally, Guggenheim assumed coverage on shares of Aerpio Pharmaceuticals in a research report on Wednesday, September 19th. They issued a “buy” rating and a $10.00 target price for the company.

TRADEMARK VIOLATION WARNING: “Aerpio Pharmaceuticals Inc (ARPO) Director Acquires $118,800.00 in Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/aerpio-pharmaceuticals-inc-arpo-director-acquires-118800-00-in-stock/2664916.html.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Read More: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.